214 related articles for article (PubMed ID: 27828896)
1. New classes of glaucoma medications.
Schehlein EM; Novack GD; Robin AL
Curr Opin Ophthalmol; 2017 Mar; 28(2):161-168. PubMed ID: 27828896
[TBL] [Abstract][Full Text] [Related]
2. New pharmacotherapy for the treatment of glaucoma.
Schehlein EM; Novack G; Robin AL
Expert Opin Pharmacother; 2017 Dec; 18(18):1939-1946. PubMed ID: 29172818
[TBL] [Abstract][Full Text] [Related]
3. Advances in medical therapy for glaucoma.
Ostler E; Rhee D; Burney E; Sozeri Y
Curr Opin Ophthalmol; 2021 Mar; 32(2):129-133. PubMed ID: 33395110
[TBL] [Abstract][Full Text] [Related]
4. Latanoprost : an update of its use in glaucoma and ocular hypertension.
Perry CM; McGavin JK; Culy CR; Ibbotson T
Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
[TBL] [Abstract][Full Text] [Related]
5. A review of additivity to prostaglandin analogs: fixed and unfixed combinations.
Tabet R; Stewart WC; Feldman R; Konstas AG
Surv Ophthalmol; 2008 Nov; 53 Suppl1():S85-92. PubMed ID: 19038627
[TBL] [Abstract][Full Text] [Related]
6. A Review of New Medications and Future Directions of Medical Therapies in Glaucoma.
Jiang Y; Ondeck C
Semin Ophthalmol; 2020 Aug; 35(5-6):280-286. PubMed ID: 33019870
[TBL] [Abstract][Full Text] [Related]
7. Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension.
Lewis RA; Levy B; Ramirez N; Kopczynski CC; Usner DW; Novack GD;
Br J Ophthalmol; 2016 Mar; 100(3):339-44. PubMed ID: 26209587
[TBL] [Abstract][Full Text] [Related]
8. Medical therapy for glaucoma: what to add after a prostaglandin analogs?
Tanna AP; Lin AB
Curr Opin Ophthalmol; 2015 Mar; 26(2):116-20. PubMed ID: 25594765
[TBL] [Abstract][Full Text] [Related]
9. Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013 - 2018).
Angeli A; Supuran CT
Expert Opin Ther Pat; 2019 Oct; 29(10):793-803. PubMed ID: 31462124
[No Abstract] [Full Text] [Related]
10. [Latanoprost topical ophthalmic combinations].
Călugăru M; Călugăru D
Oftalmologia; 2004; 48(4):18-28. PubMed ID: 15782758
[TBL] [Abstract][Full Text] [Related]
11. Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study.
Katz LJ; Rauchman SH; Cottingham AJ; Simmons ST; Williams JM; Schiffman RM; Hollander DA
Curr Med Res Opin; 2012 May; 28(5):781-8. PubMed ID: 22458918
[TBL] [Abstract][Full Text] [Related]
12. Sustained drug delivery for glaucoma: current data and future trends.
Aref AA
Curr Opin Ophthalmol; 2017 Mar; 28(2):169-174. PubMed ID: 27764023
[TBL] [Abstract][Full Text] [Related]
13. 24-hour efficacy of the bimatoprost-timolol fixed combination versus latanoprost as first choice therapy in subjects with high-pressure exfoliation syndrome and glaucoma.
Konstas AG; Holló G; Mikropoulos DG; Haidich AB; Dimopoulos AT; Empeslidis T; Teus MA; Ritch R
Br J Ophthalmol; 2013 Jul; 97(7):857-61. PubMed ID: 23686322
[TBL] [Abstract][Full Text] [Related]
14. Emerging drugs for ocular hypertension.
Lee AJ; Goldberg I
Expert Opin Emerg Drugs; 2011 Mar; 16(1):137-61. PubMed ID: 21352074
[TBL] [Abstract][Full Text] [Related]
15. Investigational drugs targeting prostaglandin receptors for the treatment of glaucoma.
Matsou A; Anastasopoulos E
Expert Opin Investig Drugs; 2018 Oct; 27(10):777-785. PubMed ID: 30227753
[TBL] [Abstract][Full Text] [Related]
16. [Fixed combination of topical prostaglandin analogue in glaucoma treatment].
Stefan C; Pop A; Cojocaru I
Oftalmologia; 2011; 55(3):82-8. PubMed ID: 22428296
[TBL] [Abstract][Full Text] [Related]
17. Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice.
Holló G; Topouzis F; Fechtner RD
Expert Opin Pharmacother; 2014 Aug; 15(12):1737-47. PubMed ID: 24998246
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications.
Noecker RJ; Walt JG
Am J Ophthalmol; 2006 Jan; 141(1 Suppl):S15-21. PubMed ID: 16389056
[TBL] [Abstract][Full Text] [Related]
19. Ocular hypotensive efficacy of bimatoprost when used as a replacement for latanoprost in the treatment of glaucoma and ocular hypertension.
Bournias TE; Lee D; Gross R; Mattox C
J Ocul Pharmacol Ther; 2003 Jun; 19(3):193-203. PubMed ID: 12828838
[TBL] [Abstract][Full Text] [Related]
20. A randomized, 36-month, post-marketing efficacy and tolerability study in Sweden and Finland of latanoprost versus non-prostaglandin therapy in patients with glaucoma or ocular hypertension.
Friström B; Uusitalo H
Acta Ophthalmol; 2010 Feb; 88(1):37-43. PubMed ID: 19900212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
